ChroMedX!
ChroMedX Collaborates with Microfluidic and Microfabrication Experts for HemoPalm Cartridge Development
Toronto, Ontario--(Newsfile Corp. - March 23, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce it has entered into a collaboration with Dr. Ravi Selvaganapathy of McMaster University to assist in the design and development of prototype cartridges for the Company's patented HemoPalm blood analyzer system.
The McMaster and ChroMedX partnership has been awarded an NSERC Engage Grant which is funded by NSERC (Natural Sciences and Engineering Research Council of Canada).
Dr. Selvaganapathy is Associate Professor in the Department of Mechanical Engineering and Canada Research Chair in Biomicrofluidics and is an expert in microfluidics and microfabrication. The project also involves Dr. Tauhiduzzaman who is a Postdoctoral Fellow in the McMaster Manufacturing Research Institute (MMRI) with expertise in microfabrication. The design will be prototyped in McMaster's Machine Systems Laboratory which is part of the McMaster Manufacturing Research Institute (MMRI) overseen by Dr. Stephen Veldhuis. It is expected that the first designs will be prototyped and tested within the next 30-60 days.
"We are very pleased with the addition of expertise in microfluidics and microfabrication through this grant that greatly complements our initiative and will provide the flexibility necessary to be successful at this stage of cartridge development. Micromachining will not only allow us to examine the various mechanical and fluidic aspects of the cartridge including activation of the calibration fluid pouch, but will also allow us to evaluate the cartridge performance during development of calibration algorithms for CO-oximetry (spectroscopic measurement of 5 hemoglobin species). Micromachining can create prototypes more quickly and at significantly lower cost compared to injection moulding, which is preferred for manufacturing the final product. Therefore design changes can be implemented in a less expensive and rapid fashion."
The cartridge will utilize a calibration fluid pouch provided by vendor ThinXXS of Zweibruken, Germany. Testing of previous versions of the pouch allowed one with superior stability to be selected.
The Company recently announced the addition of biosensor expert Mr. Steve Cozzette to the development team focusing on electrochemical sensor and cartridge development aspects of the HemoPalm platform.
Ich bin deshalb davon überzeugt, dass sie nicht mehr als 90 % an Wert verlieren wird. Denn mir ist nicht wirklich bewußt, dass von all seinen "Empfehlungen" jemals eine Aktie viel mehr an Wert verloren hat.
Deshalb kaufen?
Ich kaufe allerdings seine "Empfehlungen" niemals, führe sie jedoch in meinem virtuellen Depot.
Ich glaube, er kooperiert mit dem ganz berühmten Magister, Herausgeber und Chefredakteur Carsten Schmider, ebenfalls ein wirklich Großer dieser Branche, der ebenfalls data deposit bewerben soll.
Übrigens, bei der Aktie mezzi hat der Österreicher gut verdient.
NITE ist schon zur Stelle... ;-)
http://www.boersennews.de/nachrichten/thema/...kussprung--news/903527
Optionen
| Boardmail an "ruck" |
Wertpapier: Scryb |
